{"entity":{"id":"nct06673017","kind":"trial","name":"PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)","aka":[],"tldr":"A phase 1 trial of PTM-101 run by PanTher Therapeutics, now recruiting.","summary":"PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) is a phase 1 interventional study registered as NCT06673017 by PanTher Therapeutics, with 26 participants planned, started 2025-04-14. Conditions recorded: Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma and Pancreatic Cancer. Interventions recorded: PTM-101.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06673017","url":"https://clinicaltrials.gov/study/NCT06673017"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["ptm-101"],"companies":["panther-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06673017","phase":"1","setting":"A Phase Ib Dose Escalation/Dose Expansion Study of PTM-101 as an Adjunct to Neoadjuvant Therapy for Treatment Naïve, Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)","sponsor":"PanTher Therapeutics","enrolled":26,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06673017/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"ptm-101","kind":"drug","name":"PTM-101","route":"/drugs/ptm-101/"}],"company":[{"id":"panther-therapeutics","kind":"company","name":"PanTher Therapeutics","route":"/companies/panther-therapeutics/"}]}}